Reckitt Benckiser Group PLC Directorate Change (5986S)

TIDMRB.

RNS Number : 5986S

Reckitt Benckiser Group PLC

26 June 2018

Dr. Mehmood Khan to join RB Board, strengthening further its scientific and sustainability focus

June 26, 2018, Slough UK -Today RB is pleased to announce the appointment of Dr. Mehmood Khan to the Board, with effect from July 1(st) 2018.

Dr. Khan is the Vice Chairman and Chief Scientific Officer, Global Research and Development, at PepsiCo, the global food and beverage company with net revenues of over $63 billion.

In his role, Dr. Khan oversees the PepsiCo global Performance with Purpose sustainability initiatives, inspired by the belief that business success is inextricably linked to the sustainability of the world. Dr. Khan also leads PepsiCo's R&D efforts, creating breakthrough innovations in food, beverages and nutrition.

Prior to joining PepsiCo, Dr. Khan was President, Takeda Global Research & Development Center, overseeing Takeda Pharmaceuticals Company's worldwide R&D efforts. Previously, Dr. Khan was a faculty member at the Mayo Clinic and Mayo Medical School in Rochester, Minnesota, serving as Director of the Diabetes, Endocrine and Nutritional Trials Unit in the endocrinology division. He earned his medical degree from the University of Liverpool Medical School and is a Fellow of the Royal College of Physicians, London.

Dr. Khan is also an independent director of biopharmaceutical company CorMedix.

Commenting on the appointment, Chris Sinclair, Chairman of the Board of RB, said "I am delighted that Mehmood has agreed to join the Board. He brings enormous experience as a medical practitioner and researcher, and in the application of science to the development of consumer products, in particular in the field of nutrition. He is also a seasoned executive on the management team of a global consumer products company, with extensive experience in both developing and developed markets. I am confident that he will make a significant contribution to RB and the Board."

Dr. Khan will also join RB's Corporate Responsibility, Sustainability, Ethics and Compliance Committee which is chaired by Pam Kirby.

The Company confirms that there is no further information to be disclosed under the requirements of Listing Rule 9.6.13R in relation to Dr. Khan's appointment.

For further information, please contact:

Reckitt Benckiser [phone]

Patty O'Hayer

Finsbury [phone]

Catherine Boyle

Reckitt Benckiser Group plc's LEI code is 5493003JFSMOJG48V108

About RB

RB is the global leading consumer health, hygiene and home company. Driven by a purpose to build healthier lives and happier homes, RB has operations in over 60 countries. From the foundations of wellness and infant nutrition, to the fundamentals of a hygienic home, our global brands help people live healthier, happier lives.

RB has world leading Powerbrands which include household names such as Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang, Mortein, Finish, Vanish, Calgon, Woolite and Air Wick.

RB's unique culture is at the heart of its success. Its drive to achieve, passion to outperform and commitment to quality and scientific excellence are manifested in the work of over 40,000 RB employees worldwide.

For more information visit www.rb.com

*RB is the trading name of the Reckitt Benckiser group of companies

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

BOAPGUGGQUPRUBQ

(END) Dow Jones Newswires

June 26, 2018 05:15 ET (09:15 GMT)